CATALYST PHARMACEUTICA

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst

28 Jan 2022 12:46:42 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing

10 Jan 2022 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

06 Dec 2021 06:00:01 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

15 Nov 2021 15:15:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results

09 Nov 2021 15:15:04 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021

25 Oct 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS

30 Sep 2021 11:08:12 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

17 Sep 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

10 Sep 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations

16 Aug 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

09 Aug 2021 15:39:16 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021

26 Jul 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®

19 Jul 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

06 Jul 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors

29 Jun 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®

28 Jun 2021 15:30:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan

28 Jun 2021 07:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

03 Jun 2021 12:20:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

19 May 2021 07:03:00 By Nasdaq GlobeNewswire